Roots Analysis
FEBRUARY 20, 2022
In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization.
Roots Analysis
MARCH 13, 2022
Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. The Evolving Landscape of Biopharmaceutical Excipient Manufacturing Domain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 27, 2021
For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug formulations, particularly transdermal patches and sub-lingual (oral) strips for the delivery of active pharmaceutical ingredients (“API”) for the treatment of pain and neurological conditions.
Pharmaceutical Technology
APRIL 12, 2023
The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment. A robust manufacturing process that leads to a consistently high-quality product is a major business goal for pharmaceutical R&D.
Pharmaceutical Technology
JUNE 14, 2023
The number of high-potency drug approvals has increased over the last decade, driven by the increasing use of APIs (Active Pharmaceutical Ingredients) in the pipeline and among marketed drugs. Furthermore, the number of marketed high potency APIs (HPAPIs) tends to increase over time as more HPAPIs in development gain approval.
Expert insights. Personalized for you.
52 
Let's personalize your content